AxoGen (AXGN) Tops Q2 EPS by 9c; Reaffirms FY22 Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. QGEN
6. LVS
7. BFH
8. CSX
9. LRCX
10. NDAQ

Go back to AxoGen (AXGN) Tops Q2 EPS by 9c; Reaffirms FY22 Guidance

Axogen, Inc Reports 2022 Second Quarter Financial Results

August 3, 2022 4:01 PM EDT

ALACHUA, Fla. and TAMPA, Fla., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the second quarter ended June 30, 2022.

Second Quarter 2022 and Business Highlights

Net revenue was $34.5 million during the second quarter, an increase of 3% over the second quarter of 2021.Excluding revenue from Avive® Soft Tissue Membrane of $1.8 million in the second quarter of 2021, revenue in... More